Upstream modulation for Inflammatory Bowel Disease

Explore the science Contact us

Crohn's disease and ulcerative colitis are part of Inflammatory Bowel Disease, a larger footprint of around 4 million adults in the US.

~4.1 million

Adults with Inflammatory Bowel Disease (IBD), US

1.3 million

Crohn's disease (CD)

3.1 million

Ulcerative colitis (UC)

Segments are drawn to scale. Some adults report both diagnoses, so CD and UC together exceed the overall IBD total.

Source: Dahlhamer JM, Terlizzi EP. Inflammatory bowel disease among adults age 18 and older: United States, 2023–2024. NCHS Health E-Stat No. 122. CDC National Center for Health Statistics; August 2026.

Lacking efficacy of current therapies is apparent in patient response

Millions of mild-moderate-severe IBD patients fail to achieve durable remission. Existing therapies trade efficacy for safety, while failing to address the multiple drivers of persistent inflammation.

However, even these “safe” treatments come with serious side effects, including Black Box warnings listing serious infections, malignancies, hepatotoxicity and cardiovascular risks.

>50%

of patients fail to reach remission on current advanced therapies at 1 year

>30%

of patients lose response or remain symptomatic (urgency, pain and fatigue)

Sources: Reves J, et al. Curr Res Pharmacol Drug Discov 2021;2:100070. Qiu Y, et al. J Gastroenterol 2017;52:535-554. Fairbrass KM, et al. Lancet Gastroenterol Hepatol 2020;5(12):1053-1062.

A novel oral agent for single and combination IBD treatment

APX3330's differentiated profile expected in IBD

APX3330 (Ref-1 inhibitor) Oral tablet Convenient and Accessible Oral Tablet Attractive Safety Profile Preservation of Immune Response Mucosal Barrier Integrity Pain and Bowel Urgency Reduction Broad Acting Anti-inflammatory APX3330 (Ref-1 inhibitor) Oral tablet 1 2 3 4 5 6
  1. Convenient and Accessible Oral Tablet1
  2. Attractive Safety Profile2
  3. Preservation of Immune Response3
  4. Mucosal Barrier Integrity4
  5. Pain and Bowel Urgency Reduction5
  6. Broad Acting Anti-inflammatory6

Expected profile if approved.

More about Apexian

Interested in learning more?

Contact our team for investor, partnership and clinical inquiries, or explore our published science.

Contact us View publications